The continuum limit of the quark mass step scaling function in quenched lattice QCD

The renormalisation group running of the quark mass is determined non-perturbatively for a large range of scales, by computing the step scaling function in the Schroedinger Functional formalism of quenched lattice QCD both with and without O(a) improvement. A one-loop perturbative calculation of the discretisation effects has been carried out for both the Wilson and the Clover-improved actions and for a large number of lattice resolutions. The non-perturbative computation yields continuum results which are regularisation independent, thus providing convincing evidence for the uniqueness of the continuum limit. As a byproduct, the ratio of the renormalisation group invariant quark mass to the quark mass, renormalised at a hadronic scale, is obtained with very high accuracy.Comment: 23 pages, 3 figures; minor changes, references adde

Lymphatic vessels in human adipose tissue

Despite being considered present in most vascularised tissues, lymphatic vessels have not been properly shown in human adipose tissue (AT). Our goal in this study is to investigate an unanswered question in AT biology, regarding lymphatic network presence in tissue parenchyma. Using human subcutaneous (S-) and visceral (V-) AT samples with whole mount staining for lymphatic specific markers and three-dimensional imaging, we showed lymphatic capillaries and larger lymphatic vessels in the human VAT. Conversely, in the human SAT, microcirculatory lymphatic vascular structures were rarely detected and no initial lymphatics were found

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis

Objectives: Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study. Methods: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks’ double-blind sarilumab 150 or 200 mg every 2 weeks s.c. or tocilizumab 4 mg/kg every 4 weeks i.v., increased to 8 mg/kg if clinically indicated. In Study 1309, patients were randomized 1: 1: 1: 1 to single-dose open-label sarilumab 150 or 200 mg s.c. or tocilizumab 4 or 8 mg/kg i.v. Results: In ASCERTAIN, incidence of treatment-emergent adverse events was similar between sarilumab and tocilizumab. The most common treatment-emergent adverse events were the following: sarilumab: neutropenia [6 patients (12.2%) in the 150 mg group and 8 (15.7%) in the 200 mg group], nasopharyngitis [6 (12.2%) and 3 (5.9%)], and injection-site erythema [4 (8.2%) and 4 (7.8%)]; tocilizumab: accidental overdose [9 (8.8%)], upper respiratory tract infection [7 (6.9%)] and nausea [7 (6.9%)]. Laboratory changes in both studies included decreased neutrophils and platelets and increased transaminases and lipids. In Study 1309, incidence of absolute neutrophil count <1.0 giga/l was similar between sarilumab and tocilizumab, and occurred more frequently in the higher dose groups. No association between decrease in absolute neutrophil count and increased incidence of infection was observed in either study. Conclusion: No clinically meaningful differences in treatment-emergent adverse events were observed between sarilumab and tocilizumab. Laboratory changes with sarilumab were within the same range as those with tocilizumab

Análise da diversidade genética de genótipos de milho (Zea mays L.) a partir de caracteres morfoagronômicos.

O presente trabalho teve por objetivo avaliar a divergência genética, por meio de caracteres morfoagronômicos, de 36 híbridos de milho cultivados nas regiões norte de Mato Grosso e sudeste de Rondônia

Final results of Borexino Phase-I on low energy solar neutrino spectroscopy

Borexino has been running since May 2007 at the LNGS with the primary goal of detecting solar neutrinos. The detector, a large, unsegmented liquid scintillator calorimeter characterized by unprecedented low levels of intrinsic radioactivity, is optimized for the study of the lower energy part of the spectrum. During the Phase-I (2007-2010) Borexino first detected and then precisely measured the flux of the 7Be solar neutrinos, ruled out any significant day-night asymmetry of their interaction rate, made the first direct observation of the pep neutrinos, and set the tightest upper limit on the flux of CNO neutrinos. In this paper we discuss the signal signature and provide a comprehensive description of the backgrounds, quantify their event rates, describe the methods for their identification, selection or subtraction, and describe data analysis. Key features are an extensive in situ calibration program using radioactive sources, the detailed modeling of the detector response, the ability to define an innermost fiducial volume with extremely low background via software cuts, and the excellent pulse-shape discrimination capability of the scintillator that allows particle identification. We report a measurement of the annual modulation of the 7 Be neutrino interaction rate. The period, the amplitude, and the phase of the observed modulation are consistent with the solar origin of these events, and the absence of their annual modulation is rejected with higher than 99% C.L. The physics implications of phase-I results in the context of the neutrino oscillation physics and solar models are presented

Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission

Coexisting conditions and previous antimicrobial drug exposure predict colonization

Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas

We investigated the natural course of adrenal incidentalomas in 115 patients by means of a long-term endocrine and morphological (CT) follow-up protocol (median 4 year, range 1–7 year). At entry, we observed 61 subclinical hormonal alterations in 43 patients (mainly concerning the ACTH–cortisol axis), but confirmatory tests always excluded specific endocrine diseases. In all cases radiologic signs of benignity were present. Mean values of the hormones examined at last follow-up did not differ from those recorded at entry. However in individual patients several variations were observed. In particular, 57 endocrine alterations found in 43 patients (37.2%) were no longer confirmed at follow-up, while 35 new alterations in 31 patients (26.9%) appeared de novo. Only four alterations in three patients (2.6%) persisted. Confirmatory tests were always negative for specific endocrine diseases. No variation in mean mass size was found between values at entry (25.4±0.9 mm) and at follow-up (25.7±0.9 mm), although in 32 patients (27.8%) mass size actually increased, while in 24 patients (20.8%) it decreased. In no case were the variations in mass dimension associated with the appearance of radiological criteria of malignancy. Kaplan–Meier curves indicated that the cumulative risk for mass enlargement (65%) and for developing endocrine abnormalities (57%) over time was progressive up to 80 months and independent of haemodynamic and humoral basal characteristics. In conclusion, mass enlargement and the presence or occurrence over time of subclinical endocrine alterations are frequent and not correlated, can appear at any time, are not associated with any basal predictor and, finally, are not necessarily indicative of malignant transformation or of progression toward overt disease

Measurement of the cross-section and charge asymmetry of WW bosons produced in proton-proton collisions at s=8\sqrt{s}=8 TeV with the ATLAS detector

This paper presents measurements of the $W^+ \rightarrow \mu^+\nu$ and $W^- \rightarrow \mu^-\nu$ cross-sections and the associated charge asymmetry as a function of the absolute pseudorapidity of the decay muon. The data were collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with the ATLAS experiment at the LHC and correspond to a total integrated luminosity of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the 1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured with an uncertainty between 0.002 and 0.003. The results are compared with predictions based on next-to-next-to-leading-order calculations with various parton distribution functions and have the sensitivity to discriminate between them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables, submitted to EPJC. All figures including auxiliary figures are available at https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13